Crenolanib besylate (CP-868,596-26 or AR-868,596-26, 4-piperidinamine, 1-[2-[5-[(3-Methyl-3-oxetanyl) methoxy]-1H-benzimidazol-1-yl]- 8-quinolinyl]-, monobenzenesulfonate) is an investigational inhibitor being developed by AROG Pharmaceuticals, LLC. The compound is currently being evaluated for safety and efficacy in clinical trials for various types of cancer, including acute myeloid leukemia (AML), gastrointestinal stromal tumor (GIST), and glioma. Crenolanib is an orally bioavailable benzamidazole that selectively and potently inhibits signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases (RTK) FLT3 (FMS-like Tyrosine Kinase 3), PDGFR α (Platelet-Derived Growth Factor Receptor), and PDGFR β. Unlike most RTK inhibitors, crenolanib is a type I mutant-specific i
| Property |
Value |
| dbo:abstract |
Crenolanib besylate (CP-868,596-26 or AR-868,596-26, 4-piperidinamine, 1-[2-[5-[(3-Methyl-3-oxetanyl) methoxy]-1H-benzimidazol-1-yl]- 8-quinolinyl]-, monobenzenesulfonate) is an investigational inhibitor being developed by AROG Pharmaceuticals, LLC. The compound is currently being evaluated for safety and efficacy in clinical trials for various types of cancer, including acute myeloid leukemia (AML), gastrointestinal stromal tumor (GIST), and glioma. Crenolanib is an orally bioavailable benzamidazole that selectively and potently inhibits signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases (RTK) FLT3 (FMS-like Tyrosine Kinase 3), PDGFR α (Platelet-Derived Growth Factor Receptor), and PDGFR β. Unlike most RTK inhibitors, crenolanib is a type I mutant-specific inhibitor that preferentially binds to phosphorylated active kinases with the ‘DFG in’ conformation motif. (en) |
| dbo:alternativeName |
CP-868,596; AR-868,596-26 (en) |
| dbo:iupacName |
1-(2-{5-[(3-methyloxetan-3-yl)methoxy]-1H-benzimidazol-1-yl}quinolin-8-yl)piperidin-4-amine (en) |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Crenolanib.svg?width=300 |
| dbo:wikiPageExternalLink |
http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp%3Fdictionary=NCI%20Thesaurus&code=C64639 http://www.arogpharma.com |
| dbo:wikiPageID |
28985895 (xsd:integer) |
| dbo:wikiPageLength |
19642 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1120716924 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Structural_motif dbr:Progenitor_cell dbr:C-KIT dbr:Hypereosinophilic_syndrome dbr:Cytotoxicity dbr:Dermatofibrosarcoma_protuberans dbr:Pericytes dbc:Piperidines dbr:PDGFRA dbr:Chronic_myelomonocytic_leukemia dbr:Gastrointestinal_stromal_tumor dbr:Glioma dbr:Myelodysplastic_syndrome dbr:Lung_cancer dbr:Chinese_hamster_ovary_cell dbr:Pons dbr:Axitinib dbr:Dissociation_constant dbr:Acute_lymphoblastic_leukemia dbr:Acute_myeloid_leukemia dbc:Benzimidazoles dbc:Oxetanes dbr:PDGFRα dbr:PDGFRβ dbr:Chromosome_4 dbr:Epithelial dbr:Receptor_tyrosine_kinase dbc:Quinolines dbr:Fibroblasts dbr:Astrocytes dbc:Tyrosine_kinase_inhibitors dbr:Pathogenesis dbr:VEGF dbr:Docetaxel dbr:Bone_marrow dbr:DIPG dbr:Oncogenesis dbr:MTT_assay dbr:Mitogen-activated_protein_kinase_kinase dbr:IC50 dbr:AKT dbr:Tyrosine_kinase dbr:PDGFB dbr:PDGFRB dbr:Mesenchymal dbr:PDGF dbr:PDGFR dbr:FLT3 dbr:Phosphorylated dbr:GM-CSF dbr:Poly-glutamic_acid dbr:Wild-type dbr:Gliomas dbr:Immunoblot dbr:Chinese_hamster_ovary dbr:Hematological_malignancies dbr:Stromal dbr:BFUE dbr:MV411 dbr:Molm14 |
| dbp:imagefile |
Crenolanib.svg (en) |
| dbp:imagesize |
200 (xsd:integer) |
| dbp:iupacname |
1 (xsd:integer) |
| dbp:othernames |
CP-868,596; AR-868,596-26 (en) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
443232265 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:wikiPageUsesTemplate |
dbt:Chembox dbt:Chembox_Hazards dbt:Chembox_Identifiers dbt:Chembox_Properties dbt:Citation_needed dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:Growth_factor_receptor_modulators dbt:ClinicalTrialsGov |
| dcterms:subject |
dbc:Piperidines dbc:Benzimidazoles dbc:Oxetanes dbc:Quinolines dbc:Tyrosine_kinase_inhibitors |
| gold:hypernym |
dbr:Inhibitor |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q11173 yago:WikicatTyrosineKinaseInhibitors yago:Agent114778436 yago:CausalAgent100007347 yago:Drug103247620 yago:Matter100020827 yago:Medicine103740161 yago:PhysicalEntity100001930 dbo:ChemicalCompound dbo:Drug yago:Substance100020090 yago:TyrosineKinaseInhibitor104506005 |
| rdfs:comment |
Crenolanib besylate (CP-868,596-26 or AR-868,596-26, 4-piperidinamine, 1-[2-[5-[(3-Methyl-3-oxetanyl) methoxy]-1H-benzimidazol-1-yl]- 8-quinolinyl]-, monobenzenesulfonate) is an investigational inhibitor being developed by AROG Pharmaceuticals, LLC. The compound is currently being evaluated for safety and efficacy in clinical trials for various types of cancer, including acute myeloid leukemia (AML), gastrointestinal stromal tumor (GIST), and glioma. Crenolanib is an orally bioavailable benzamidazole that selectively and potently inhibits signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases (RTK) FLT3 (FMS-like Tyrosine Kinase 3), PDGFR α (Platelet-Derived Growth Factor Receptor), and PDGFR β. Unlike most RTK inhibitors, crenolanib is a type I mutant-specific i (en) |
| rdfs:label |
Crenolanib (en) |
| owl:sameAs |
freebase:Crenolanib yago-res:Crenolanib wikidata:Crenolanib dbpedia-sh:Crenolanib dbpedia-sr:Crenolanib https://global.dbpedia.org/id/4iPLh |
| prov:wasDerivedFrom |
wikipedia-en:Crenolanib?oldid=1120716924&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Crenolanib.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Crenolanib |
| is dbo:wikiPageRedirects of |
dbr:C26H29N5O2 dbr:CP-868,596 |
| is dbo:wikiPageWikiLink of |
dbr:ETV6 dbr:PDGFRA dbr:C26H29N5O2 dbr:Platelet-derived_growth_factor_receptor dbr:List_of_drugs:_Cp–Cz dbr:CP-868,596 |
| is foaf:primaryTopic of |
wikipedia-en:Crenolanib |
